<div id="readability-page-1"><p>In a report released today, John Newman from Canaccord Genuity maintained a Buy rating on Allogene Therapeutics, with a price target of <span id="expert-recommendation-target">$14.00</span>.</p><h3>Claim 55% Off TipRanks</h3><ul><li>Unlock  hedge fund-level data  and  powerful investing tools  for smarter, sharper decisions  </li><li> Discover top-performing stock ideas and upgrade to a portfolio of market leaders with  Smart Investor Picks  </li></ul> <p>Newman covers the Healthcare sector, focusing on stocks such as Nuvalent, Delcath Systems, and Compass Therapeutics. According to TipRanks, Newman has an average return of <span>3.8%</span> and a 42.42% success rate on recommended stocks. </p> <p>Allogene Therapeutics has an analyst consensus of Strong Buy, with a price target consensus of $8.71.</p></div>

ALLO

LABU

SBIO

<p>Canaccord Genuity analyst John Newman has maintained a Buy rating on Allogene Therapeutics (ALLO) with a price target of $14.00. Newman, who focuses on the Healthcare sector, has an average return of 3.8% and a 42.42% success rate on his stock recommendations. The analyst consensus for Allogene Therapeutics is a Strong Buy, with a price target consensus of $8.71.</p>

Tip Ranks

Allogene Therapeutics

SPDR S&P Biotech

First Trust NYSE Arca Biotech Index Fd

VanEck Biotech ETF

iShares Biotechnology ETF

Invesco Biotechnology & Genome ETF

Direxion S&P Biotech Bull 3X

Proshares Ultra Nasdaq Biotech

ALPS Medical Breakthrough

Nuvalent

Delcath

Compass Therapeutics

Canaccord Genuity Remains a Buy on Allogene Therapeutics (ALLO)